ELVN
NASDAQ · Pharmaceuticals
Enliven Therapeutics Inc
$41.26
+0.97 (+2.41%)
Open$40.53
Previous Close$40.29
Day High$42.48
Day Low$40.53
52W High$48.53
52W Low$14.79
Volume—
Avg Volume559.2K
Market Cap2.45B
P/E Ratio—
EPS$-1.86
SectorPharmaceuticals
Analyst Ratings
Strong Buy
16 analysts
Price Target
-23.2% upside
Current
$41.26
$41.26
Target
$31.67
$31.67
$20.91
$31.67 avg
$36.06
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 263.34M | 235.73M | 210.63M |
| Net Income | 79.58M | 63.75M | 57.56M |
| Profit Margin | 30.2% | 27.0% | 27.3% |
| EBITDA | 141.73M | 119.11M | 111.32M |
| Free Cash Flow | 52.28M | 61.02M | 35.31M |
| Rev Growth | -0.5% | +12.7% | -7.4% |
| Debt/Equity | 0.42 | 0.43 | 0.43 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $948.45 | -2.72% | 36.1 | 913.24B |
| JNJ | Johnson & Johnson | $221.32 | -0.53% | 26.1 | 548.94B |
| MRK | Merck & Co. Inc. | $111.38 | -0.82% | 31.3 | 279.42B |
| PFE | Pfizer Inc. | $25.68 | -3.02% | 19.3 | 150.09B |
| BMY | Bristol-Myers Squibb Co | $56.16 | -0.16% | 17.0 | 120.08B |
| ZTS | Zoetis Inc | $82.83 | -5.13% | 21.5 | 57.37B |